Skip to Content
Developmental Therapeutics Program (DTP)
Last Updated: 05/28/15

Confidential Disclosure Agreement/
Material Transfer Agreement

Submitters or their appropriate institutional signatory authority are required to agree to a standard, non-negotiable combined Confidential Disclosure Agreement/Material Transfer Agreement (CDA/MTA) for all submission requests for NCI60 testing. The agreement also covers follow-up in vivo testing which includes, but is not limited to, the hollow-fiber assay and xenograft evaluation.

The CDA/MTA agreement process is executed on-line. Instructions can be found in the NCI60 Submission Request Procedure section.

CDA/MTA document